TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Biocon Limited ( (IN:BIOCON) ) just unveiled an update.
Biocon Limited announced that its subsidiary, Biocon Pharma Limited, has received approval from the US FDA for its ANDA for Everolimus Tablets, which are used in organ transplantation. This approval enhances Biocon’s portfolio of complex drug products, potentially strengthening its market position and offering new opportunities for growth.
More about Biocon Limited
Biocon Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of complex drug products. The company is known for its vertically integrated approach and serves markets with a focus on prescription medications.
YTD Price Performance: -17.25%
Average Trading Volume: 164,169
Current Market Cap: 366.4B INR
See more data about BIOCON stock on TipRanks’ Stock Analysis page.